Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo Q1 Sales Rise 6.2% on Robust Enhertu Performance, Weaker Yen
Daiichi Sankyo’s April-June group sales increased 6.2% from the previous year. Its oncology business franchise fared well, up 8.8 billion yen with sales of the antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) hauling in 26.7 billion yen. In the first quarter…
To read the full story
Related Article
- Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
May 12, 2026
- Daiichi Sankyo’s Profit Down on HER3-DXd Delay, One-Off CMO Costs
November 4, 2025
- Daiichi Sankyo Plays Down Tariff Impact for FY2025, Eyes US Production Boost
August 1, 2025
- Daiichi Sankyo Marks 2-Digit Growth in Sales, Net Profit Driven by Enhertu
April 28, 2025
- Daiichi Sankyo Ups Outlook on Earnings Growth Driven by Enhertu
November 1, 2024
- Daiichi Sankyo’s Q1 Sales Grow 24% as Mainstays Fare Well
August 1, 2024
- Daiichi Sankyo Ups FY2025 Sales Goal to 2.1 Trillion Yen on Bullish Cancer Biz
April 26, 2024
- Daiichi Sankyo Ups Full-Year Outlook on Growth of Flu, COVID Products
February 1, 2024
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
- Daiichi Sankyo Enjoys Rosy Q1 Earnings on Strong Mainstays
August 1, 2023
- Daiichi Sankyo on Path to Net 2 Trillion Yen in Sales by FY2025 on Robust Core Products
April 28, 2023
- Daiichi Sankyo’s Revenue Up 16.9% in April-December on Buoyant Mainstays
February 1, 2023
- Daiichi Sankyo Nets Double-Digit Rise in H1 Sales as Major Products Fare Well
November 1, 2022
- Daiichi Sankyo Breaks 1 Trillion Mark in FY2021 Sales on Bullish Enhertu, Lixiana
April 28, 2022
- Daiichi Sankyo’s Revenue Rises 9.8% in April-December on Upbeat Mainstays
February 1, 2022
- Daiichi Sankyo’s 1st Half Operating Profit Jumps 44.9% Thanks to Lixiana, Enhertu
November 1, 2021
- Daiichi Sankyo’s Q1 Sales Surge on Upbeat Global Brands
August 2, 2021
- Daiichi Sankyo Sales Slip in FY2020 as Price Cuts, Deal Termination Weigh
April 28, 2021
- Daiichi Sankyo’s Revenue Down 2.4% in April-December as Mainstays Flounder at Home
February 1, 2021
- Daiichi Sankyo’s 6-Month Operating Profit Falls 32% on Higher SGA Costs for Enhertu, ADC R&D Spending
November 2, 2020
- Daiichi Sankyo Sales Skid 4.9% on Coronavirus, Price Cuts; Enhertu, Edoxaban Upbeat
August 3, 2020
BUSINESS
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
- Nipro Pharma Recalls Topical Drugs over Long-Running Manufacturing Deviations
July 16, 2026
- JCR to File DMD Drug Givinostat in Japan by End-2026
July 16, 2026
- Daiichi Sankyo Healthcare to Take Over Claritin EX Sales in Japan
July 16, 2026
- Maruishi Set to Secure Japan Rights to Kringle’s Vocal Fold Scar Drug
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…